0
Editorial |

Anti-IL-5 for Severe Asthma: Aiming High to Achieve Success

Richard Russell, MBBS; Christopher E. Brightling, PhD, FCCP
Author and Funding Information

FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: C. E. B. has received, through his institution, grant and or consultancy funding, or both, from AZ/MedImmune, GSK, Novartis, Roche/Genentech, Chiesi, Pfizer, Theravance, and Vectura. None declared (R. R.).

Department of Infection, Immunity and Inflammation, Institute for Lung Health, Glenfield Hospital, University of Leicester, Leicester, England

CORRESPONDENCE TO: Christopher E. Brightling, PhD, FCCP, University of Leicester, Glenfield General Hospital, Leicester, LE3 9QP, UK


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4):766-768. doi:10.1016/j.chest.2016.06.013
Text Size: A A A
Published online

Extract

Asthma affects > 300 million people worldwide and is severe in 10% of these individuals. Advances in approaches to phenotype the heterogeneity of severe asthma have established the importance of eosinophilic inflammation, and several new therapies beyond corticosteroids and anti-immunoglobulin E are designed to target type 2-mediated immunity to inhibit this inflammation, with the aim of reducing exacerbation frequency. Current therapies against type 2 immunity include anti-IL-4Rα, IL-5, IL-5R, IL-13, and the type 2 prostaglandin D2 receptor.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Topics

asthma

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543